Prostate Cancer Academy 2017 Summaries - Wikidata - awgldk - TriplyDB

Prostate Cancer Academy 2017 Summaries

Prostate Cancer Academy 2017 Summaries

http://www.wikidata.org/entity/Q57118607

about

Prostate Cancer Academy 2017 Summaries

http://www.wikidata.org/entity/Q57118607

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2017

@uk

name

Prostate Cancer Academy 2017 Summaries

@en

Prostate Cancer Academy 2017 Summaries

@nl

type

label

Prostate Cancer Academy 2017 Summaries

@en

Prostate Cancer Academy 2017 Summaries

@nl

prefLabel

Prostate Cancer Academy 2017 Summaries

@en

Prostate Cancer Academy 2017 Summaries

@nl

P1433

Q57118607-9E240A3E-7891-46C0-8029-CEEC49756BBA

P1476

Q57118607-7006A1C8-63A0-44A4-A6A5-C3F6C8F21965

P2093

Q57118607-158502FE-E6D0-4EB5-B7F3-E4458523A68C

P2860

Q57118607-07F8FE43-F8D2-4803-95F7-41DF3ABC8B3D

Q57118607-0B039789-AB61-4542-B278-EBE8B7113FBA

Q57118607-156FBD1F-35FF-4207-9FF8-4E791D3B6D10

Q57118607-1A8F0E09-0B7E-4A3B-8EEF-3ED32AD7A750

Q57118607-314CD4A7-A265-4074-8CF6-901227E2ADEE

Q57118607-4D7871BA-4AE0-4AD1-B749-B5DAD823CCA7

Q57118607-4DAB8495-6D8C-4BE2-8174-47547D77BDE4

Q57118607-5AEB78D8-96DC-4460-BFC1-3726F8AB87FD

Q57118607-5FD0DB37-991D-4222-BA6D-AA4A1B00BF53

Q57118607-6AE8F62B-1C18-406C-89DC-E630BBAB2A67

P304

Q57118607-3E2D1AD9-F09D-4AB3-89AF-4847923B5C2D

P31

Q57118607-88338932-89A5-4102-BFD3-EEA9096ED152

P356

Q57118607-C802F613-838A-479A-BC4E-349DFD664A52

P407

Q57118607-5F6E6BA0-220B-42AD-8490-63AE94F4F308

P433

Q57118607-D04B7447-EA73-4B2C-8EA8-4C09E01A0AFF

P478

Q57118607-57F51E8D-7C1B-4477-9990-79429D120926

P577

Q57118607-C8DC2CC2-BA3E-4F64-892F-E43CC167B8FF

P698

Q57118607-205D6439-A17B-4D87-9BF9-EF89925BDC9B

P932

Q57118607-9A2DC6B2-004C-4927-908C-90C2F62B5B60

P356

P1433

Reviews in urology

P1476

Prostate Cancer Academy 2017 Summaries

@en

P2093

Dmitry Volkin

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Enzalutamide in metastatic prostate cancer before chemotherapy.

A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.

Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy.

Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer.

Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer.

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.

P304

252-260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3909/RIU0783

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29472829

http://www.w3.org/2001/XMLSchema#string

P932

5811883

http://www.w3.org/2001/XMLSchema#string